Dr. Tannir on Results With Telaglenastat/Cabozantinib in mRCC
June 7th 2021
Nazir Tannir, MD, FACP, discusses the efficacy of the combination of telaglenastat and cabozantinib in patients with metastatic renal cell carcinoma, as demonstrated in the phase 2 CANTATA trial.